Pay in 4 interest-free payments of $5.02 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
International Journal of Pharmaceutical Research, 12(04)
Key Points Native human GLP-1 normalizes hyperglycaemia in patients with type 2 diabetes mellitus, but the short in vivo half-life of this hormone limits its therapeutic application A number of synthetic GLP-1 receptor agonists, with half-lives between 23 h and several days, have been developed for the long-term treatment of type 2 diabetes mellitus Short-acting GLP-1 receptor agonists (such as exenatide and lixisenatide) predominantly lower postprandial glucose levels and insulin concentrations via retardation of gastric emptying Long-acting GLP-1 receptor agonists (such as albiglutide, dulaglutide, exenatide long-acting release and liraglutide) predominantly lower blood glucose levels through stimulation of insulin secretion and reduction of glucagon levels Adverse effects of GLP-1 receptor agonists include nausea, vomiting and diarrhoea, injection-site reactions, antibody formation and increased heart rate This is a preview of subscription content, access via your institution Access options Subscribe to this journal Receive 12 print issues and online access $189.00 per year only $15.75 per issue Buy this article Purchase on SpringerLink Instant access to the full article PDF
Mol Carcinog 45(10):732740
Atherosclerosis 173 , 321328 (2004)
Clinical study was conducted at Chula Clinical Research Center, Faculty of Medicine, Chulalongkorn University
US$ 26.67
US$ 23.90
US$ 21.58
US$ 26.45
US$ 27.50
US$ 27.80
US$ 24.45
US$ 26.98
US$ 26.64
US$ 25.43
US$ 20.18
US$ 22.14
